P
rostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer deaths in men today, with Ͼ184,500 new cases of prostate cancer and 42,000 deaths. 1 Although prostate cancer can be detected in earlier stages, thanks to the development of diagnoses such as prostate-specific antigen screening over recent years, and therefore may be cured or maintained successfully, there are still no effective therapies for those individuals who have been diagnosed with advanced disease; the prognosis is dismal for this group of patients. A novel treatment for this devastating, common disease is desperately needed. As prostate cancer represents an accumulation of genetic mutations resulting in a prostate cell that has gone awry, one new approach against prostate cancer may be gene therapy. Inactivation of tumor-suppressor genes has been shown to be a common event in both familial and acquired cancers, and may be the initiating event in tumorigenesis. A corrective gene therapy strategy to replace critical tumor-suppressor genes may be effective against many cancers. Adenovirally mediated p53 tumor-suppressor gene therapy has been shown to be efficacious against colorectal cancer, 2 prostate cancer, 3, 4 breast cancer, 5, 6 cervical cancer, 7 ovarian carcinoma, 8 and melanoma. 9 Recently, a retrovirus (LXSN) expressing the BRCA1 tumor-suppressor gene was used in a phase I human clinical trial for advanced prostate cancer. 10 The identification of key tumor-suppressor genes that may successfully inhibit or destroy prostate cancer cells is paramount. One such gene appears to be the tumorsuppressor gene p16 (also known as MTS1, INK4A, and CDKN2). The tumor-suppressor gene p16 is an important negative cell cycle regulator whose functional loss may significantly contribute to malignant transformation. The cyclin-dependent kinases (CDKs) are essential enzymes whose activity is tightly regulated by protein phosphorylation in association with other proteins called cyclins.
11 -13 The activation of CDK-cyclin complexes is responsible for the orderly transition of the cell through the cell cycle; the CDK-cyclin complex phosphorylates the retinoblastoma protein (pRb), which promotes cell cycle progression. In contrast, CDK inhibitors prevent the activation of CDK-cyclin complexes, and pRb remains in its growth-suppressive, hypophosphorylated form, which arrests cell cycle transition. The abnormal activation of CDK activity or overexpression of cyclins may lead to the uncontrolled growth characteristic of cancer. One important CDK inhibitor is p16, which specifically inhibits CDK4 and CDK6. 14 The p16 gene resides in the chromosome 9p21 region. [15] [16] [17] Ectopic expression of p16 inhibited cell growth in melanoma cell lines, 18 in glioma cell lines, 19 and in primary rat embryo fibroblasts transformed by oncogenes Ha-ras and myc. 20 Overexpression of p16 arrests cell division in cell lines with an intact pRb protein. 21 Many tumors, including transitional cell carcinoma, melanoma, leukemia, and glioma tumors, contain heterozygous or homozygous deletions of the 9p21 region. [22] [23] [24] [25] Subtle mutations of the p16 gene have also been reported in a variety of tumor cell lines and in some primary tumors. 17,26 -28 Germline alterations of the p16 gene have been found in a subset of patients with familial melanoma. 29 Moreover, deletion of p16 genes has also been found in brain tumors, 15 in adult T-cell leukemia, 30 in childhood acute lymphoblastic leukemia, 31 in non-small cell lung cancers, 32, 33 in primary malignant mesothelioma, 34 in gliomas, 35 and in human pancreatic cell carcinoma lines. 36 Expression of p16 has also been found to be abnormal in 40% of prostate cancer patients (Greenberger MD, et al., submitted for publication), and a homozygous loss of p16 gene was found in 40% of prostate cancers. 37 Accordingly, the rate of homozygous loss of p16 makes this one of the most frequent events in a wide range of tumors. 15 Another common mechanism that leads to p16 inactivation in prostate cancer is hypermethylation of the p16 promoter region. 38, 39 The majority of human prostate cancer cell lines were reported to have hypermethylation of the promoter, including TSU-Pr, 40 PC-3, 40, 41 and PPC-1 cells; 40 DU145 cells have a missense mutation in the coding sequence. 41 Thus, p16 inactivation by genetic mutations, allelic loss, or hypermethylation of the promoter is a common event not only in prostate cancer but also in other cancers. [22] [23] [24] [25] 42 In this study, we found that human prostate cancer was suppressed markedly with a replication-defective, recombinant, E1/E3-deleted adenovirus containing a truncated Rous sarcoma virus (RSV) promoter and the wild-type (wt) p16 tumor-suppressor gene. Animals bearing human prostate cancer xenografts treated with AdRSVp16 also had longer survival. In addition, AdRSVp16-mediated growth inhibition was due in part to the induction of senescence. Thus, replacement of the p16 tumor-suppressor gene by adenoviral vector gene therapy may be a new and promising approach for the treatment of locally advanced prostate cancer.
MATERIALS AND METHODS

Cell lines and tissue culture conditions
The human prostate cancer cell lines PPC-1, DU145, PC-3, LNCaP, and TSU-Pr1 (all obtained from the American Type Culture Collection (ATCC), Manassas, Va) were grown in RPMI 1640 medium (Cellgro, Herndon, Va) containing 10% fetal bovine sera (Hyclone Laboratories, Logan, Utah) at 37°C and 5% CO 2 . The human embryonic kidney cell line 293 (ATCC) was grown in Dulbecco's modified Eagle's medium (Cellgro) containing 10% heat-inactivated fetal bovine sera at 37°C and 5% CO 2 . All cell lines tested negative for mycoplasma.
Northern blot
Cells were extracted, and total RNA was isolated using an RNeasy kit (Qiagen, Santa Clarita, Calif). Total RNA was loaded on a 1.2% polyacrylamide gel and processed to electrophoresis. Standard Northern blot transfer to a nylon membrane (Hybond-N ϩ ; Amersham Life Science, Little Chalfont, UK) was performed as described previously. 43 The cDNA probe of p16 was labeled by [␣-
32 P]deoxycytidine triphosphate using the random primer method (Prime-It II Kit; Stratagene, La Jolla, Calif). The membrane was hybridized with the probe in Rapid-hyb buffer (Amersham) according to the manufacturer's protocol. The membrane was exposed to a Kodak x-ray film (Eastman Kodak, Rochester, NY) between two intensifying screens at Ϫ80°C for autoradiography. The ␤-actin cDNA probe was labeled as described above and used as an internal control for normalization.
Construction of adenoviral vectors
A human p16 cDNA gene was subcloned under the control of a truncated RSV promoter (395 bp) into an E1/E3-deleted adenoviral shuttle vector. The resultant adenoviral shuttle vector was cotransfected into 293 cells with pJM17, 44 an adenoviral type 5 genome plasmid, by the calcium phosphate method. 45 Individual plaques were screened for recombinant AdRSVp16 by polymerase chain reaction using specific primers for both the RSV promoter and p16 DNA sequences. Adenovirus expressing the Escherichia coli ␤-galactosidase (␤-gal) gene (AdRSVlacZ) was similarly constructed and used to assess transduction efficiency, level of gene expression, and duration of gene expression. Single viral clones were propagated in 293 cells. The culture medium of the 293 cells showing the completed cytopathic effect was collected, and the adenovirus was purified and concentrated by CsCl 2 gradient ultracentrifugation two times. Viral titration and transduction were performed as described previously. 46 
Western blot
Cells were extracted and processed for gel electrophoresis as described previously. 47 Cell extract lysates (100 g) were loaded on 12% polyacrylamide gels, subjected to sodium dodecyl sulfate gel electrophoresis, and subsequently transferred to a nitrocellulose membrane (Bio-Rad Laboratories, Hercules, Calif). The membrane was treated with blocking solution (15% nonfat milk, 0.02% sodium azide in phosphatebuffered saline (PBS)) overnight at 4°C. The membrane was incubated for 1 hour at room temperature with mouse antihuman p16 monoclonal antibody (Ab) (Santa Cruz Biotechnology, Santa Cruz, Calif). Next, the membrane was incubated for 1 hour at room temperature with goat anti-mouse secondary Ab coupled to peroxidase (enhanced chemiluminescence kit, Amersham Life Science, Arlington Heights, Ill); enhanced chemiluminescence was performed according to the manufacturer's protocol. p16 in vitro studies using human prostate cancer cell lines Stable p16 subclones. A human p16 cDNA gene was subcloned under the control of an inducible MMTV promoter into the pMAMneo expression vector (Invitrogen, Carlsbad, Calif). The resultant p16 plasmid was transfected into PC-3 cells by Lipofectamine (Life Technologies, Gaithersburg, Md). The transfectants were selected in medium containing 600 g/mL G418 (Life Technologies). Cells were plated at 5 ϫ 10 5 cells/well in 6-well plates in medium containing 1 M dexamethasone (Dex) at 37°C. The cell number was counted in duplicate daily using a Coulter cell counter (Coulter, Luton, Beds, UK) from day 1 to day 7.
AdRSVp16 in vitro studies. Human prostate cancer cells were infected with AdRSVp16 in vitro at a multiplicity of infection (MOI) of 200. After viral infection, cells were incubated at 37°C; cell numbers were determined daily from day 1 through day 12 after viral infection.
5-bromo-4-chloro-3-indolyl-␤-D-galactoside (X-Gal) staining of AdRSVlacZ-transduced tumors
Human prostate xenograft tumors were established by injecting 5 ϫ 10 6 PPC-1 cells subcutaneously (s.c.) into the flanks of male nude mice (Harlan Sprague-Dawley, Indianapolis, Ind). When tumors reached ϳ50 mm 3 , AdRSVlacZ (1 ϫ 10 9 or 1 ϫ 10 10 plaque-forming units (PFU)) was injected directly into the tumors. Tumors were harvested at days 3 and 14. A portion of the tumor sample was processed and frozen in optimal cutting temperature compound (Tissue-Tek/Sakura, Torrance, Calif). Cryosections were stained with X-Gal solution (Life Technologies) as described previously. 48 Whole tumors were fixed for 1 hour at 4°C in PBS containing 4% paraformaldehyde, rinsed with PBS twice, and incubated overnight in fresh X-Gal solution (1 mg/mL X-Gal, 10 mM K 4 Fe(CN) 6 , 10 mM K 4 Fe(CN) 6 , 2 mM MgCl 2 , 0.01% sodium deoxycholate, and 0.02% Nonidet P-40 in PBS). The tumors were then postfixed for 24 hours in PBS containing 2.5% glutaraldehyde, 1% formaldehyde, and 0.01% sodium deoxycholate.
p16 immunohistochemistry
Tumor samples were embedded in paraffin using a tissue processor (Citadel 2000; Shandon, Pittsburgh, Penn) and sectioned using a microtome. The 5-M sections were first incubated with 1% H 2 O 2 for 30 minutes. The sections were then incubated with anti-p16 Ab (catalog no. SC-759, dilution 1/300; Santa Cruz Biotechnology) for 16 hours at 4°C, and subsequently with secondary Ab and a Universal Elite avidinbiotin complex kit (Vector Laboratories, Burlingame, Calif) according to the manufacturer's protocol. The reaction was visualized with DAB solution (75 mg of 3,3Ј-diaminobenzidine and 30 L of 50% H 2 O 2 in 150 mL of PBS) for 3-10 minutes.
In vivo studies using PPC-1 xenograft tumors
Human prostate cancer cells (1 ϫ 10 7 cells in 0.2 mL of PBS) were injected s.c. into the flanks of male nude mice (Harlan Sprague-Dawley). When the tumors reached an average volume of 50 mm 3 , 4 ϫ 10 9 PFU adenoviral vectors (AdRSVp16 or AdRSVlacZ) or PBS alone for untreated controls were injected directly into the tumor. Tumor volume was measured every 2 days until the animals were euthanized. Any animal that showed any distress or had a tumor burden that was Ͼ15% of their total body weight was sacrificed. Tumor samples were collected and processed for hematoxylin and eosin staining. The survival differences were determined by log-rank test using SAS software (SAS Systems, Cary, NC).
X-Gal staining for senescence-associated ␤-gal
Cells were fixed in 1% glutaraldehyde, 10 mM NaH 2 PO 4 , 150 mM NaCl, and 1 mM MgCl 2 at 37°C for 45 minutes; after a brief washing with PBS three times, the cells were then incubated at 37°C overnight in substrate solution containing 1 mg/mL X-Gal, 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 150 mM NaCl, 1 mM MgCl 2 , 40 mM citric acid, and 40 mM NaH 2 PO 4 (pH 6.0).
RESULTS
p16 expression in various prostate cancer cells
To determine p16 gene status in various prostate cancer cells, five human cancer cell lines were subjected to p16 Northern blot analysis (Fig 1) . The DU145 cell line had an apparent single 0.9-kb transcript, whereas the LNCaP, PC-3, PPC-1, and TSU cell lines had weak expression or no detectable expression of p16 mRNA. The absence or insignificant presence of p16 mRNA in the PC-3, PPC-1, and TSU cell lines was consistent with previous reports of hypermethylation of the promoter region of p16 in those cell lines. 40 , 41 Although we did not detect any evident p16 mRNA in LNCaP cells, there have been reports that p16 was expressed in LNCaP cells. 41, 49 The presence of p16 mRNA for DU145 cells was expected, as this cell line has been recently found to have a missense mutation of p16. 41 At the protein level, we did not detect endogenous p16 expression in PPC-1 and PC-3 cells (see Fig 2 and Fig 6A) .
Stable transfection of p16 plasmid inhibited prostate cancer cell growth A mammalian p16 expression vector under the control of the inducible MMTV promoter was stably transfected into PC-3 cells. The expression of p16 was determined by Western blot analysis (Fig 2) . PC-3 cells had no detectable endogenous p16 protein, whereas PC-3 cells stably transfected with MMTV-p16 expression vector had Dexinducible p16 protein when grown in medium containing 1 M Dex. To determine whether the introduction of wt p16 would affect PC-3 cellular proliferation, parental, control vector-transfected, and MMTV-p16-transfected PC-3 cells were cultured in medium both in the presence and absence of 1 M Dex. Cells were counted daily for 7 days. In the absence of 1 M Dex, both parental PC-3 cells and control plasmid-transfected PC-3 (PC-3/Vector) cells grew at similar growth rates, indicating that neither Dex nor vector had an effect on PC-3 cellular growth. PC-3 cells transfected with MMTV-p16 expression vector also grew at a growth rate similar to parental and control plasmid-transfected PC-3 cells in the absence of 1 M Dex (data not shown). When growing in medium with 1 M Dex, parental and control plasmidtransfected PC-3 cells again had similar growth rates (Fig 3) . In contrast, the cellular proliferation of PC-3 cells transfected with MMTV-p16 expression vector (PC-3/pMAMp16) was significantly growth inhibited by day 4, with a 70% reduction in cell number compared with the parental PC-3 cells and vector control PC-3 cells by day 7 (Fig 3) . (Fig 2) , indicating that the transfer of p16 by AdRSVp16 into p16-negative PC-3 cells results in p16 protein expression.
Prostate cancer cell growth inhibited by AdRSVp16
To determine the effects of p16 on the cell growth of human prostate cancer cell lines, PPC-1 and PC-3 were treated with AdRSVp16, AdRSVlacZ (control vector), or no virus in vitro. AdRSVp16 significantly inhibited the growth of PPC-1 and PC-3 cells (95% and 51% inhibition, respectively) compared with cells transduced with control virus (Fig 4) . Interestingly, PPC-1 cells, which were derived from a primary human prostate cancer sample, had greater growth suppression by wt p16 than did PC-3 cells, which were procured from metastatic human prostate cancer specimens. These findings suggest that the adenovirally mediated introduction of wt Adenovirally mediated transgene expression in xenograft prostate tumors First, the transduction efficiency, the level and distribution of transgene expression, and the duration of transgene expression were determined for the adenovirus type 5, E1/E3-deleted, RSV vector in vivo. An adenovirus RSV vector that was identical except for the fact that it contained a reporter lacZ gene (AdRSVlacZ) was employed to transduce PPC-1 prostate cancer xenografts growing in nude mice in vivo. Tumors were grown to an average size of 50 mm 3 . The tumors were then injected with 10 9 PFU or 10 10 PFU of AdRSVlacZ. Next, prostate tumors were harvested at 3 days and analyzed by histological and whole-mount X-Gal staining. As shown in Figure 5 , an AdRSVlacZ dose of 10 9 PFU resulted in a transduction rate of 80%, compared with a 95% transduction rate for 10 10 PFU, as determined by the percentage of cancer cells that exhibited blue staining. Interestingly, the distribution of the adenoviral particles radiated in a uniform pattern throughout the tumor, as shown in Figure 5 , C and D. Thus, a single dose of 4 ϫ 10 9 PFU of adenoviral vector was selected for further studies using AdRSVp16 in prostate cancer in vivo. The p16 overexpression in xenograft tumors after AdRSVp16 transduction was also confirmed by immunohistochemical staining of tumor sections by anti-p16 Ab (Fig 6) .
The duration of transgene expression after adenoviral vector delivery of the transgene in vivo was determined in PPC-1 tumors. PPC-1 tumors (average volume of 50 mm 3 ) were treated by a single injection of 10 10 PFU of AdRSVlacZ and harvested for X-Gal analysis at days 3 and 14 after viral injection. Adenovirally mediated lacZ expression was still detectable by 14 days, but with a 75% reduction in lacZ expression (Fig 7) . Thus, significant adenovirally mediated transgene expression in vivo can be expected for at least 14 days. Taken together, these results suggest that adenoviral vectors have efficient gene transfer and expression in prostate tumors after a single injection. Moreover, expression of the transgene decreased, but persisted for Ͼ2 weeks.
AdRSVp16 inhibited prostate tumor growth in vivo
To evaluate the effects of AdRSVp16 treatment on prostate cancer cell growth in vivo, PPC-1 human prostate tumors were established in nude mice by injecting 1 ϫ 10 7 PPC-1 cells s.c. into the flanks of nude mice. By day 10 after the injection of cells, animals bearing tumors with an average volume of 50 mm 3 were divided into three groups: AdRSVp16-treated (n ϭ 8), AdRSVlacZ control virus-treated (n ϭ 8), and untreated (n ϭ 8). Treated tumors were injected with a single dose of 4 ϫ 10 9 PFU of either the control virus or AdRSVp16. As shown in Figure 8 , untreated and control virus-treated PPC-1 tumors grew rapidly relative to the AdRSVp16-treated tumors. PPC-1 tumors transduced with control virus also had an initial, albeit minor, inhibition after viral administration. This inhibitory effect was nonspecific, as tumor volume for viral controltreated and untreated PPC-1 tumors was similar. By day 21 after viral injection, the tumor burden in nude mice bearing untreated and control virus-treated PPC-1 tumors reached 15% of the total body weight; accordingly, these animals were euthanized. In contrast, PPC-1 tumors transduced by AdRSVp16 had a significant reduction in tumor volume compared with untreated and control virus-treated PPC-1 tumors. By day 21 after viral injection, the volume of AdRSVp16-transduced PPC-1 tumors was 33% of untreated and control virus-treated PPC-1 tumor volume (660 mm 3 for AdRSVp16-treated tumors versus 1899 mm 3 for untreated tumors and 1739 mm 3 for control virus-treated PPC-1 tumors) (Fig 8) . To comply with the animal study policy of the National Institutes of Health guidelines, any mouse whose tumor burden reached Ͼ15% of its total body weight was sacrificed; in these instances, the days between viral postinjection and sacrifice were recorded as survival time. The survival time of animals bearing AdRSVp16-treated PPC-1 tumors was significantly longer than for those animals bearing untreated and control-virus treated PPC-1 tumors. By day 21 (day 31 after tumor cell inoculation in Fig 9) after viral injection, 100% of the animals bearing untreated and control virus-treated tumors were sacrificed; in contrast, by day 40 (day 50 after tumor cell inoculation in Fig 9) after viral injection, 50% of the mice carrying AdRSVp16-transduced PPC-1 tumors were still alive. By day 50 (day 60 after tumor cell inoculation in Fig 9) after viral injection, 100% of the nude mice bearing AdRSVp16-treated tumors were euthanized because of tumor burden. Thus, animals bearing AdRSVp16-treated tumors had a survival rate that was two times longer than animals bearing un- treated and control virus-treated tumors (Fig 9) . The survival differences between mice bearing PPC-1 control tumors (or mice bearing control virus-treated tumors) and mice bearing AdRSVp16-treated tumors are statistically significant (P ϭ .0319, Ͻ0.05 as determined by log-rank test using SAS software).
AdRSVp16 induced senescence in prostate cancer cells
One observation in the in vitro study was that the phenotype of prostate cancer cells transduced by AdRSVp16 was also altered. Unlike the control and control virus-treated 9 PFU (C) and 1 ϫ 10 10 PFU (D)) were stained by X-Gal to determine the expression of lacZ transgene. E: An X-Gal staining of a cryosection of an untreated control PPC-1 tumor to show that PPC-1 tumor did not express endogenous ␤-gal activity.
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PPC-1 cell lines, AdRSVp16-transduced PPC-1 cells were markedly enlarged (Fig 10, compare A or B with C and D). The AdRSVp16-transduced cells were large and swollen, with a morphology (Fig 10C) similar to that observed in other cell types undergoing senescence; these cells eventually became detached and nonviable (Fig 10D) . To determine whether the cells were indeed undergoing senescence, a senescence marker, senescence-associated ␤-gal at a pH of 6.0, was assessed in AdRSVp16-transduced cells. Whereas both untreated and control virus-transduced PPC-1 cells had no detectable blue cells with X-Gal staining, AdRSVp16-transduced cells had the characteristic senescence-associated blue coloration in the cytoplasm of cells with X-Gal staining at a pH of 6.0 (Fig 11, A-D) . To determine whether the AdRSVp16-transduced cells that were exhibiting a senescence phenotype and positive X-Gal staining were indeed expressing the p16 protein, a double staining technique using both senescenceassociated X-Gal and p16 immunohistochemistry was used. As demonstrated in Figure 11 , E and F, the cells undergoing senescence also had intense p16 expression. Taken together, these results suggest that p16 mediates growth inhibition by inducing senescence in prostate cancer cells. Interestingly, apoptosis was not seen in AdRSVp16-treated cells, as determined by DNA laddering analysis and Comet assay (data not shown).
DISCUSSION
Loss of functional p16 is a common event in cancer progression Inactivation of p16 tumor-suppressor gene is one of the most common events in a wide range of tumors. Loss of heterozygosity, homozygous deletions, mutations, and promoter hypermethylation have been found in a wide variety of malignancies, including malignant melanoma; 50 mesothelioma; 32 leukemia; 51 glioma; carcinomas of the lung, colon, liver, kidney, 50 esophagus, pancreas, breast, ovary, biliary tract, and prostate; and sarcomas. 37, 50, [52] [53] [54] In some of the major cancers, p16 loss is quite common, with a frequency as high as 85% for 25, 37 and up to 46% for prostate cancer (Greenberger MD, et al., submitted for publication). 37, 40, 41 The emerging body of evidence has also shown that p16 loss correlates with prostate tumor progression. 40,59 -61 In prostate cancer, p16 inactivation is a common event in the majority of human prostate cancer cell lines 40, 41 and alterations of p16 have also been reported in patients who have prostate cancer (Greenberger MD, et al., submitted for publication). 37 PC-3, PPC-1, TSU-Pr1, and Du-Pro-1 have hypermethylation of the p16 promoter region, 39 -41 whereas the DU145 cell line has a missense mutation (GAC3 TAC; Asp to Tyr) in exon 2, codon 76. 40, 62 Among patients who have prostate cancer, a 20 -40% frequency of homozygous deletions in p16 was observed. 37, 40 With progression, prostate cancer metastatic lesions have a 46% loss of heterozygosity. Even more interesting, patients who have failed androgen deprivation have a 71% loss of 9p allelic loss, 63 suggesting that the majority of patients with refractory prostate cancer may be excellent candidates for p16 replacement. Thus, alterations of p16 expression occur frequently in cancer, raising the question of whether or not p16 gene replacement may inhibit cancer growth. The restoration and expression of p16 has shown the ability to suppress the growth of a variety of tumor types including non-small cell carcinoma of the lung, 15 glioma cells, 64 prostate carcinoma, 65 hepatocellular carcinoma, 66 and others. Adenovirally mediated p16 gene transfer induced growth arrest in glioma cells 67 and inhibited the proliferation of esophageal cancer. 68 Retrovirally mediated p16 gene transfer had a growth-inhibitory effect in acute lymphoblastic leukemias. 69 Adenovirus E1-deleted cytomegalovirus p16 vectors (AdCMVp16) had significant growth inhibition in vitro for cancer cell lines, including the HuH7 human hepatocellular carcinoma cell line; the human breast cancer cell lines MCF7 and BT549; the human cervical cancer cell line C33A; Lovo human colon cancer cells; 66 the human lung cancer cell lines H460, H322, and H226Br (United States Patent no. 5691198); and the prostate cancer cell lines LNCaP, C4-2, DU145, and PC-3.
65 E1/E3-deleted adenovirus with a truncated RSV promoter containing p16 gene appeared to have a greater growth-suppressive effect on PPC-1 prostate cancer cells both in vitro and in vivo compared with AdCMVp16.
Although the majority of this study was done with PPC-1 cells, our recent results also show that AdRSVp16 effectively suppressed cellular growth in DU145 cells. 70 Although the PC-3, DU145, and LNCaP cell lines are the most popular human prostate cancer lines studied in this field, the PPC-1 line is the only one that is derived from a human primary prostate carcinoma rather from a metastasis of the primary prostate cancer (such as LNCaP, DU145, and PC-3). Therefore, results from the PPC-1 line may better reflect and represent the actual situation for the current approach of gene therapy (i.e., by direct intraprostatic injection of viral vector into the primary cancer site, the prostate). Mechanism of p16 inhibition: apoptosis versus senescence Although various hypothetical mechanisms for p16/ CDK4-cyclin D complex regulation of the pRb pathway have been suggested, [71] [72] [73] the mechanism by which p16 inhibits tumor growth remains to be elucidated. The concurrent inhibition of cell proliferation and induction of apoptosis by p53 3, 7, 9 may represent a common inhibitory mechanism used by tumor-suppressor genes that regulate pRb phosphorylation, including p16. Combined overexpression of p16, but not p53 on its own, induces efficient apoptotic death in the majority of tumor cells, 66 suggesting that p16 may play a role in apoptosis. However, in our study we did not detect significant apoptosis in PPC-1 cells treated with AdRSVp16 by several apoptosis assays.
Another possible molecular mechanism of p16 action is the induction of senescence. 74 The level of p16 in primary human fibroblasts is very low, but p16 mRNA and proteins accumulate to high levels in senescent cells. 75 Embryo fibroblast cells from p16 knockout mice show no sign of senescence phase at population-doubling levels far beyond the point at which normal cells enter senescence. 76 Loss of p16 expression has been linked to immortality in several human head and neck keratinocyte cell lines. 77 In human uroepithelial cells, elevated p16 levels have been demonstrated in senescent cells, whereas p16 was undetectable in immortal E6 transformed cells. 78 Fibroblasts derived from patients who have Li-Fraumeni syndrome have a loss of p53 and inactivation of p16 by hypermethylation. 79 Demethylation of these cells using 5-aza-2Ј-deoxycytidine induced the expression of p16 protein. The fibroblast became growth-arrested, and the phenotype changed to an enlarged, flat morphology with an increase in the following senescence markers: lipofuscin granules and endogenous ␤-gal at a pH of 6.0. 79 Malignant glioma cells had cell growth arrest, an increase in cell size, and induction of senescence after induction of the p16 gene. 80 A similar phenotype has also been described in glioma cells after adenovirally mediated p16 gene transfer. 67 Immortal human fibroblasts can be induced to senescence by infection with retrovirus expressing p16. 79 Consistent with all of these studies, induction of senescence was observed in cells transduced by AdRSVp16. Therefore, the mechanism by which p16 mediates the inhibition of prostate cancer cellular growth is by inducing cells to senescence. We are currently exploring whether an intact pRb is required for p16-induced senescence in prostate cancer cells.
In summary, AdRSVp16 vectors efficiently transduced prostate cancer cells both in vitro and in vivo. Moreover, tumors injected with AdRSVp16 had a uniform distribution of transgene expression, and the duration of expression lasted for at least 14 days. Replacement of p16 suppressed prostate cancer cell proliferation in vitro and markedly reduced tumor size in vivo. Given the duration of transgene expression, repeat treatment with AdRSVp16 may be appropriate to further suppress tumor growth. Interestingly, p16 replacement may make cancer cells more susceptible to death by other standard cancer therapies, as p16 was shown to increase the radiation sensitivity of human malignant melanoma cells. 81 This finding suggests that combinations of p16 gene therapy and radiation may be an even more effective approach in the treatment of cancer. Although the exact mechanism of p16 inhibition in cancer remains to be elucidated, the role of senescence is apparently important. Thus, AdRSVp16 gene therapy should be considered for human clinical trials against prostate cancer.
